Hetastarch Pregnancy and Breastfeeding Warnings

Brand names: Hespan, Hextend

Medically reviewed by Drugs.com. Last updated on Jul 19, 2023.

Hetastarch Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk.

US FDA pregnancy category: Not assigned.

Risk Summary: Animal studies demonstrated embryocidal effects when this drug was given IV during organogenesis in a daily dose one-half of the maximum recommended human dose, and when given intraperitoneally, from the 16th to the 21st day of pregnancy in a daily dose 2.3 times the maximum recommended human dose.

Comments:
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

Animal studies have revealed embryocidal effects when given during organogenesis. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

See references

Hetastarch Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments:
-The effects in the nursing infant are unknown.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer